Galecto Biotech AB
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Dec 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Polymorphic forms and process (US 10,307,403) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Feb 6, 2027The maintenance fee for Polymorphic forms and process (US 10,369,136) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 2 fees due May 5 to 28, 2027 · next May 5
- 1 fee due Jul 7, 2027The maintenance fee for Galactoside inhibitor of galectins (US 10,526,360) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 2 fees due Sep 5 to 26, 2027 · next Sep 5
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 27 US 12,774,298 Amorphous Form of 5-Bromopyridin-3-YL 3-Deoxy-3-[4-(3,4,5-Trifluorophenyl)-1H-1,2,3-Triazol-1-YL]-1-THIO-ALPHA-D-GALACTOPYRANOSIDE
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,799,482 | Polymorphic forms and process In force · USPTO record | In force | USPTO record | |
| US 10,526,360 | Galactoside inhibitor of galectins In force · USPTO record | In force | USPTO record | |
| US 11,377,464 | Galactoside inhibitor of galectins In force · USPTO record | In force | USPTO record | |
| US 11,919,921 | Galactoside inhibitor of galectins In force · USPTO record | In force | USPTO record | |
| US 10,464,964 | Galactoside inhibitor of galectins In force · USPTO record | In force | USPTO record | |
| US 10,774,102 | Galactoside inhibitor of galectins In force · USPTO record | In force | USPTO record | |
| US 10,730,902 | 1,1 ′-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins In force · USPTO record | In force | USPTO record | |
| US 10,307,403 | Polymorphic forms and process In force · USPTO record | In force | USPTO record | |
| US 10,369,136 | Polymorphic forms and process In force · USPTO record | In force | USPTO record | |
| US 10,889,610 | Alpha-D-galactoside inhibitors of galectins In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 20: 2 patents in force now held by others · 10 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 13 no status recorded
Showing 1 to 10 of 17, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 17/736,571 | Once-Daily Treatment of Pulmonary Fibrosis | May 4, 2022 | Abandoned |
| 18/264,488 | Novel Galactoside Inhibitor of Galectins | Feb 7, 2022 | Abandoned |
| 18/259,146 | Novel Galactoside Inhibitor of Galectins | Dec 22, 2021 | Pending |
| 18/257,382 | Dec 21, 2021 | No status recorded | |
| 18/258,656 | Dec 20, 2021 | No status recorded | |
| 17/221,201 | Apr 2, 2021 | No status recorded | |
| 17/915,690 | Mar 29, 2021 | No status recorded | |
| 17/785,295 | Large Scale Process | Dec 16, 2020 | Pending |
| 17/622,501 | Jun 24, 2020 | No status recorded | |
| 17/285,225 | Oct 9, 2019 | No status recorded |
10 of 17 applications shown.
Pro members see all 17 published applications.